For patients with severe renal impairment, the SmPCs for semaglutide and liraglutide do not recommend specific dose adjustments, but advise caution due to limited experience in this population and potential dehydration risks from gastrointestinal side effects
Recently, they have also been increasingly prescribed off-label for weight loss purposes
Oral administration of PF-06882961 shows evidence of glucose-lowering in healthy human study participants PF-06882961 was selected as a candidate for clinical studies based on its in vitro and in vivo pharmacologic and disposition profile, including potent agonism of the GLP-1R, preclinical disposition attributes (e.g., low metabolic CL int in human hepatocytes), good safety margins versus the hERG channel (IC 50 = 4.3 M, Table S4) and broad panel screening (Table S8), and selectivity versus related class B GPCRs (Table S9)
On November 6, 2025, the president announced that agreements have been reached with Eli Lilly and Novo Nordisk, the manufacturers of the three available GLP-1s for weight loss, to reduce the drugs prices
And as David pointed out, weve known for 150 years since hes the pioneering research of this brilliant French physiologist named Claude Bernard, that the brain controls whats called intermediate metabolism as well as behavior, and that its effects on intermediate metabolism, which is everything that happens after you eat a food and before you excrete it